Валюты / REGN
REGN: Regeneron Pharmaceuticals Inc
549.07
USD
13.43
(2.39%)
Курс REGN за сегодня изменился на -2.39%. При этом минимальная цена на торгах достигала 546.28, а максимальная — 562.68.
Следите за динамикой Regeneron Pharmaceuticals Inc. Котировки в реальном времени помогут быстро реагировать на изменения рынка. Переключаясь между различными таймфреймами, можно отслеживать тенденции и динамику курса по минутам, часам, дням, неделям и месяцам. Используйте эту информацию для прогнозирования изменений на рынке и принятия взвешенных торговых решений.
- M5
- M15
- M30
- H1
- H4
- D1
- W1
- MN
Новости REGN
- Investor's Business Daily Stock Market Today: Dow Falls As American Express Tumbles; Advanced Micro Leads Nasdaq Higher (Live Coverage)
- Seeking Alpha AnaptysBio: Potential Promise, But Some Cause For Skepticism (NASDAQ:ANAB)
- Investor's Business Daily Stock Market Holds At Record Highs Despite Trump Tariffs: Weekly Review
- Benzinga Trump Threatens 200% Pharma Tariffs, But Analyst Says This Stock Is Immune And Expected To 'Benefit' From Levies - AbbVie (NYSE:ABBV), Amgen (NASDAQ:AMGN)
- Investing Regeneron stock price target raised to $584 from $560 at UBS on Eylea outlook
- Seeking Alpha Eli Lilly Comes Out As ADA Winner (NYSE:LLY)
- Investor's Business Daily Merck Plots $10 Billion Takeover Of COPD Drugmaker Verona Pharma
- MarketWatch Merck dives into COPD treatments with $10 billion purchase of Verona Pharma
- Investing Bernstein reiterates Outperform rating on Regeneron stock at $750
- TipRanks QQQ ETF News, 7/8/2025 - TipRanks.com
- Investing California fails to stop 23andMe founder from re-acquiring company
- Investing JPMorgan reiterates Overweight rating on Regeneron stock ahead of Q2 earnings
- Investor's Business Daily Apogee Dives. But It Could Eventually Rival Sanofi's Biggest Moneymaker.
- The Motley Fool 2 Beaten-Down Stocks to Buy and Hold
- Investing Regeneron stock maintains Buy rating at TD Cowen on Lynozyfic approval
- Benzinga Regeneron's Lynozyfic Gains Accelerated FDA Approval For Heavily Pre-Treated Multiple Myeloma - Regeneron Pharmaceuticals (NASDAQ:REGN)
- Investing US FDA approves Regeneron’s blood cancer therapy
- Investing Regeneron stock rises after FDA approval for blood cancer therapy
- Investing Regeneron’s linvoseltamab receives FDA approval for multiple myeloma
- Investor's Business Daily Heart Drug Stock Rockets 20% On Sales, Boosts Outlook; Regeneron Pharma's Global Partnership Is Strong Tailwind
- Investing Regeneron to Report Second Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2025
- Investing CRISPR Therapeutics stock maintains outperform rating at William Blair
- TipRanks QQQ ETF News, 6/26/2025 - TipRanks.com
- Investing Maia Biotechnology enters stock purchase agreement for up to $587,905 with Prevail Partners
Дневной диапазон
546.28
562.68
Годовой диапазон
476.48
1211.20
- Предыдущее закрытие
- 570.59
- Open
- 562.50
- Bid
- 549.07
- Ask
- 549.37
- Low
- 546.28
- High
- 562.68
- Объем
- 1.163 K
- Дневное изменение
- -2.39%
- Месячное изменение
- 4.79%
- 6-месячное изменение
- -17.91%
- Годовое изменение
- -48.54%
15 июля, вторник
11:00
ALL
- Акт.
- Прог.
- Пред.
12:30
USD
- Акт.
- 0.3%
- Прог.
- -0.3%
- Пред.
- 0.1%
12:30
USD
- Акт.
- 0.2%
- Прог.
- 0.2%
- Пред.
- 0.1%
12:30
USD
- Акт.
- 2.7%
- Прог.
- 2.4%
- Пред.
- 2.4%
12:30
USD
- Акт.
- 2.9%
- Прог.
- 2.7%
- Пред.
- 2.8%
12:30
USD
- Акт.
- 322.561
- Прог.
- 321.516
- Пред.
- 321.465
12:30
USD
- Акт.
- 327.600
- Прог.
- 327.606
- Пред.
- 326.854
12:30
USD
- Акт.
- -0.4%
- Прог.
- 0.1%
- Пред.
- 0.3%
12:30
USD
- Акт.
- 0.3%
- Прог.
- Пред.
- 0.2%
12:30
USD
- Акт.
- 0.3%
- Прог.
- Пред.
- 0.2%
12:30
USD
- Акт.
- 321.500
- Прог.
- 320.395
- Пред.
- 320.580
12:30
USD
- Акт.
- 328.364
- Прог.
- Пред.
- 327.509
12:30
USD
- Акт.
- 5.5
- Прог.
- 2.2
- Пред.
- -16.0
13:15
USD
- Акт.
- Прог.
- Пред.
15:00
USD
- Акт.
- 0.3%
- Прог.
- 0.2%
- Пред.
- 0.2%
16:45
USD
- Акт.
- Прог.
- Пред.